Effects of angiotensin-converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats

被引:12
|
作者
Zhang, RY
Wang, LF [1 ]
Zhang, L
Meng, XN
Li, SJ
Wang, WR
机构
[1] Harbin Med Coll, Clin Hosp 1, Dept Cardiol, Harbin 150001, Peoples R China
[2] Harbin Med Coll, Clin Hosp 1, Dept Pathol, Harbin 150001, Peoples R China
关键词
Smad; ventricular remodeling; angiotensin converting enzyme inhibitor; angiotensin II type I receptor blocker;
D O I
10.1097/00029330-200604020-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Transforming growth factor (TGF) beta(1)-Smads signal plays an important role in cardiac remodeling following myocardial infarction (MI). In addition, both angiotensin converting enzyme inhibitor (ACEI) and angiotensin II type I receptor blocker (ARB) can effectively prevent left ventricular remodeling. The current study focused on whether the combination of ACEI and ARB is more beneficial for preventing ventricular remodeling and whether Smad proteins mediate this beneficial effect. Methods MI was induced by ligating the left anterior descending coronary artery in rats. Twenty-four hours after ligation, the survived rats were randomly divided into five groups and treated for 8 weeks: placebo group, ACEI group (benazepril 10 mg (.) kg(-1) (.) d(-1)), ARB group (irbesartan 50 mg (.) kg-(1 .) d(-1)), ACEI + ARB group (benazepril 10 mg (.) kg (.) d(-1) + irbesartan 50 mg (.) kg (.) d(-1)) and control group (sham-operated rats). After 8 weeks, we examined the following indexes: the ratio of ventricular weight to body weight,(VW/BW), left ventricular end diastolic dimension (LVDd), ejection fraction (EF), fractional shortening (FS), ratio of E-wave to A-wave velocity, collagen of noninfarcted zone, the mRNA expression of TGF beta(1), Smad 2, and Smad 3 by RT-PCR in noninfarcted zone, the protein expression of Smad 2 and Smad 3 in noninfarcted zone by Western blot. Results VW/BW significantly increased in the placebo groups compared with that in the control group (P < 0.01). This increase was limited in ACEI, ARB, and combined groups (P < 0.01 compared with placebo group). There was no significant difference among the three actively treated groups. Collagen was increased in placebo group (5.68 +/- 0.5)% compared with that in control group (P < 0.01). ACEI, ARB and combined treatment attenuated this increase of collagen [(4.3 +/- 0.5)%, (3.5 +/- 0.5)%, (3.2 +/- 0.4)%] in comparison with that in placebo group (P < 0.01 respectively). Combined treatment showed more significant effect on collagen deposition. EF and FS significantly decreased, LVDd and E/A significantly increased in placebo group compared with that in control group (P < 0.01 respectively). ACEI, ARB and combined treatment ameliorated these indexes (P < 0.01 compared with placebo group). The mRNA expression of TGF beta(1), Smad 2, and Smad 3 (0.700 +/- 0.045, 0.959 +/- 0.037 and 0.850 +/- 0.051) increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective in decreasing TGF beta(1) and Smad mRNA expression than ACEI treatment (P < 0.01). The expression of Smad 2 and Smad 3 protein increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective than ACEI alone (P < 0.01). Conclusions TGF beta(1)-Smads signal activation is correlated with ventricular remodeling following MI. ACEI and ARB treatment prevents ventricular remodeling by inhibiting expression of Smad 2 and Smad 3.. ARB and combined treatment are more effective than ACEI alone.
引用
收藏
页码:649 / 655
页数:7
相关论文
共 50 条
  • [21] The Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril and the Angiotensin II Type 1 Receptor Blocker Losartan on Fracture Healing in Rats
    Bayar, Ahmet
    Turan, Ali
    Gulle, Kanat
    Akpolat, Meryem
    Turan, Inci
    Turhan, Egemen
    CLINICAL AND INVESTIGATIVE MEDICINE, 2015, 38 (04): : E164 - E172
  • [22] Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats
    Dupuis, F
    Atkinson, J
    Limiñana, P
    Chillon, JM
    JOURNAL OF HYPERTENSION, 2005, 23 (05) : 1061 - 1066
  • [23] Olmesartan is an angiotensin II receptor blocker with an inhibitory effect of angiotensin-converting enzyme
    Agata, Jun
    Ura, Nobuyuki
    Yoshida, Hideaki
    Shinshi, Yasuyuki
    Sasaki, Haruki
    Hyakkoku, Masaya
    Taniguchi, Shinya
    Shimamoto, Kazuaki
    JOURNAL OF HYPERTENSION, 2006, 24 : 208 - 208
  • [24] Olmesartan Is an Angiotensin II Receptor Blocker with an Inhibitory Effect on Angiotensin-Converting Enzyme
    Jun Agata
    Nobuyuki Ura
    Hideaki Yoshida
    Yasuyuki Shinshi
    Haruki Sasaki
    Masaya Hyakkoku
    Shinya Taniguchi
    Kazuaki Shimamoto
    Hypertension Research, 2006, 29 : 865 - 874
  • [25] Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme
    Agata, Jun
    Ura, Nobuyuki
    Yoshida, Hideaki
    Shinshi, Yasuyuki
    Sasaki, Haruki
    Hyakkoku, Masaya
    Taniguchi, Shinya
    Shimamoto, Kazuaki
    HYPERTENSION RESEARCH, 2006, 29 (11) : 865 - 874
  • [26] Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor
    Sleight, Peter
    JOURNAL OF HYPERTENSION, 2009, 27 : S23 - S29
  • [27] Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient
    Jarred, Ghassan
    Kennedy, R. Lee
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2010, 1 (01) : 23 - 28
  • [28] Combination therapy with angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist synergistically suppresses chronic pancreatitis in rats
    Yamada, T
    Kuno, A
    Masuda, K
    Ogawa, K
    Nakamura, S
    Ando, T
    Okamoto, T
    Sano, H
    Nakazawa, T
    Ohara, H
    Nomura, T
    Joh, T
    Itoh, M
    GASTROENTEROLOGY, 2004, 126 (04) : A105 - A106
  • [29] Successful treatment of severe hypertension with the combination of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker
    Tanemoto, M
    Abe, T
    Obara, N
    Abe, M
    Satoh, F
    Ito, S
    HYPERTENSION RESEARCH, 2003, 26 (10) : 863 - 868
  • [30] Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin h receptor blocker therapy in heart failure
    Yasumura, Y
    Miyatake, K
    Okamoto, H
    Miyauchi, T
    Kawana, M
    Tsutamoto, T
    Kitakaze, M
    Matsubara, H
    Takaoka, H
    Anzai, T
    Himeno, H
    Yokoyama, H
    Yokoya, K
    Shintani, U
    Hashimoto, K
    Koretsune, Y
    Nakamura, Y
    Imai, K
    Maruyama, S
    Masaoka, Y
    Sekiya, M
    Shiraki, T
    Shinohara, H
    Ozono, K
    Matsuoka, T
    Miyao, Y
    Nomura, F
    CIRCULATION JOURNAL, 2004, 68 (04) : 361 - 366